RecruitingNCT07226804
Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules
Sponsor
M.D. Anderson Cancer Center
Enrollment
30 participants
Start Date
Nov 14, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To observe the outcomes of nsPFA therapy to treat benign thyroid nodules.
Eligibility
Min Age: 18 Years
Inclusion Criteria11
- Eligibility Criteria
- Scheduled to undergo ultrasound guided nsPFA as standard of care
- Age 18 to 80 years.
- Capable of providing independent consent.
- Presence of biopsy-confirmed benign thyroid nodule , defined as one of the following:
- Benign FNA X 2 or
- Benign US guided FNA X 1 + benign thyroid nodule ultrasound appearance (TI-RADS 2) or
- Benign FNA X 1 and radiographic/laboratory evidence of functional nature
- Nodule measuring >2cm in greatest dimension
- Presence of compressive symptoms reasonably attributable to thyroid nodule (i.e. pressure sensation, dysphagia, dysphonia, respiratory distress)
- No abnormal cervical lymph nodes during screening visit .
Exclusion Criteria2
- Age <18
- Patients considered unsuitable for nsPFA by the treating physician
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERQuestionnaire
patient-reported outcomes questionnaire
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07226804
Related Trials
RFA of Benign Thyroid Nodules: Clinical Outcomes and Quality of Life Study
NCT051893141 location
Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)
NCT076017631 location
The Outcomes of Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules
NCT063409451 location
Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters
NCT071307731 location
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation
NCT0680821732 locations